Anebulo Pharmaceuticals Dividend

Dividend criteria checks 0/6

Anebulo Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.3%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$0.40
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Feb 18

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Jul 03

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 07

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Nov 19

Anebulo Pharmaceuticals to launch private investment in public equity financing

Sep 26

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03

Sep 09

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 28

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 15

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Nov 04

Anebulo Pharmaceuticals reports FQ3 results

Jun 21

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ANEB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANEB's dividend payments have been increasing.

Dividend Yield vs Market

Anebulo Pharmaceuticals Dividend Yield vs Market

How does ANEB dividend yield compare to the market?
Segment	Dividend Yield
Company (ANEB)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Pharmaceuticals)	2.3%
Analyst forecast in 3 Years (ANEB)	n/a

Notable Dividend: Unable to evaluate ANEB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANEB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ANEB's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ANEB has not reported any payouts.

Anebulo Pharmaceuticals Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Anebulo Pharmaceuticals, Inc., Annual General Meeting, Nov 20, 2023

New major risk - Share price stability

Anebulo Pharmaceuticals, Inc. Appoints Richie Cunningham as CEO

New major risk - Financial position

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Anebulo Pharmaceuticals, Inc. Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Price target decreased to US$8.00

High number of new and inexperienced directors

Anebulo Pharmaceuticals, Inc. Appoints Nat Calloway as Class II Director

Anebulo Pharmaceuticals, Inc., Annual General Meeting, Oct 28, 2022

Anebulo Pharmaceuticals, Inc. announced that it has received $6.646748 million in funding from 22NW, LP, Nantahala Capital Management, LLC, Brightleaf Capital, ADAR1 Capital Management, LLC, and other investors

Anebulo Pharmaceuticals, Inc. announced that it expects to receive $6.646748 million in funding from 22NW, LP and other investors

Anebulo Pharmaceuticals, Inc. Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals to launch private investment in public equity financing

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03

Anebulo Pharmaceuticals Announces Positive Topline Data for Aneb-001 from A Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Anebulo Pharmaceuticals, Inc.(NasdaqCM:ANEB) dropped from Russell Microcap Value Index

Anebulo Pharmaceuticals, Inc. Announces Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

Anebulo Pharmaceuticals, Inc. Appoints Kenneth Cundy as Chief Scientific Officer

Anebulo Pharmaceuticals, Inc. Appoints Kenneth Cundy as Chief Scientific Officer

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of A Phase 2 Clinical Trial and Provides Guidance on IND Submission

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Anebulo Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Anebulo Pharmaceuticals, Inc Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial

Anebulo Pharmaceuticals reports FQ3 results

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies